US 12,466,859 B2
Desmoglein 2 (DSG2) binding proteins and uses therefor
Andre Lieber, Seattle, WA (US); and Hongjie Wang, Seattle, WA (US)
Assigned to UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION, Seattle, WA (US)
Filed by UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION, Seattle, WA (US)
Filed on Sep. 27, 2023, as Appl. No. 18/475,950.
Application 18/475,950 is a continuation of application No. 17/559,391, filed on Dec. 22, 2021, granted, now 11,820,795.
Application 17/559,391 is a continuation of application No. 16/806,617, filed on Mar. 2, 2020, granted, now 11,248,028, issued on Feb. 15, 2022.
Application 16/806,617 is a continuation of application No. 16/206,448, filed on Nov. 30, 2018, granted, now 10,611,803, issued on Apr. 7, 2020.
Application 16/206,448 is a continuation of application No. 15/593,578, filed on May 12, 2017, granted, now 10,150,798, issued on Dec. 11, 2018.
Application 15/593,578 is a continuation of application No. 14/429,803, granted, now 9,688,727, issued on Jun. 27, 2017, previously published as PCT/US2014/057139, filed on Sep. 24, 2014.
Application 14/429,803 is a continuation in part of application No. PCT/US2013/061431, filed on Sep. 24, 2013.
Claims priority of provisional application 61/954,822, filed on Mar. 18, 2014.
Prior Publication US 2024/0083953 A1, Mar. 14, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/075 (2006.01); A61K 35/761 (2015.01); A61K 47/42 (2017.01); C07K 7/06 (2006.01); C07K 14/005 (2006.01); C12N 5/077 (2010.01); C12N 7/00 (2006.01); C12N 15/10 (2006.01); C12N 15/86 (2006.01); C12N 15/861 (2006.01); G01N 33/94 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 47/42 (2013.01); C07K 7/06 (2013.01); C12N 5/0652 (2013.01); C12N 7/00 (2013.01); C12N 15/10 (2013.01); C12N 15/86 (2013.01); G01N 33/94 (2013.01); A61K 38/00 (2013.01); C07K 2319/74 (2013.01); C12N 2501/998 (2013.01); C12N 2506/00 (2013.01); C12N 2710/10022 (2013.01); C12N 2710/10033 (2013.01); C12N 2710/10321 (2013.01); C12N 2710/10322 (2013.01); C12N 2710/10333 (2013.01); G01N 2500/02 (2013.01); G01N 2500/20 (2013.01)] 29 Claims
 
1. A method for enhancing access to epithelial cells, the method comprising administering to a subject with a disorder associated with epithelial cells:
a) a cellular immunotherapy agent; and
b) a recombinant AdB-⅔ fiber polypeptide, comprising:
one or more AdB-⅔ fiber polypeptide shaft domain motifs;
an AdB-⅔ fiber polypeptide knob domain operatively linked to and located C-terminal to the one or more AdB-⅔ fiber polypeptide shaft domain motifs,
wherein the AdB-⅔ fiber polypeptide knob domain comprises the peptide of SEQ ID NO: 4 wherein:
X2 is H, L, or P;
X3 is K or E;
X4 is T, F, S, or L;
X5 is V, or D;
X6 is E or G;
X7 is Y or F;
X8 is T, K, or E; and
X9 is N or S; and
wherein at least one of the following is true: X2 is P; X3 is E; X4 is S, or L; X5 is D; X6 is G; X7 is F; X8 is E; or X9 is S; and
one or more non-AdB-⅔-derived dimerization domains operatively linked to and located N-terminal to the one or more AdB-⅔ fiber polypeptide shaft domain motifs.